Milestone Scientific Inc. (MLSS) 10-Year Financial Performance & Capital Metrics

MLSS • • Industrial / General

HealthcareMedical InstrumentsSurgical & Interventional DevicesSpecialized Therapeutic Devices

AboutMilestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.Show more

Revenue $9M -12.2%
EBITDA -$7M +4.6%
Net Income -$5M +32.0%
EPS (Diluted) -0.06 +37.9%
Gross Margin 74.56% +7.9%
EBITDA Margin -77.86% -8.6%
Operating Margin -78.3% -8.3%
Net Margin -54.62% +22.5%
ROE -68.09% +11.5%
ROIC -121.32% +17.8%
Debt/Equity 0.06 +21.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 5 (bottom 5%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-1.79%

5Y0.6%

3Y-5.74%

TTM7.84%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-50.9%

EPS CAGR

10Y-

5Y-

3Y-

TTM-41.94%

ROCE

10Y Avg-92.65%

5Y Avg-72.17%

3Y Avg-78.44%

Latest-94.19%

Peer Comparison

Specialized Therapeutic Devices

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RMDResMed Inc.	38.05B	260.70	27.41	9.84%	27.35%	23.49%	4.37%	0.14
ZJYLJin Medical International Ltd.	22.54M	0.14	6.13	18.57%	10.94%	16.93%		0.41
FEMYFemasys Inc.	38.2M	0.64	-0.76	51.97%	-9.61%	-434.6%		3.23
NYXHNyxoah S.A.	221.59M	5.15	-2.85	3.98%	-14.85%	-164.31%		0.20
MLSSMilestone Scientific Inc.	22.8M	0.29	-4.91	-12.19%	-76.78%	-208.8%		0.06
NVCRNovoCure Limited	1.55B	13.80	-8.85	18.82%	-27.66%	-52.05%		1.90
EKSOEkso Bionics Holdings, Inc.	22.43M	8.55	-15.27	-1.94%	-70.74%	-107.8%		0.47
PLSEPulse Biosciences, Inc.	955.52M	14.10	-15.33		-868.99%	-80.62%		0.08

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	9.49M	10.48M	11.28M	9.62M	8.37M	5.44M	10.3M	8.81M	9.83M	8.63M
Revenue Growth %	-0.08%	0.1%	0.08%	-0.15%	-0.13%	-0.35%	0.9%	-0.15%	0.12%	-0.12%
Cost of Goods Sold+	3.05M	4.18M	4.31M	5.19M	2.66M	1.82M	3.99M	3.91M	3.03M	2.2M
COGS % of Revenue	0.32%	0.4%	0.38%	0.54%	0.32%	0.33%	0.39%	0.44%	0.31%	0.25%
Gross Profit+	6.44M	6.31M	6.97M	4.43M	5.72M	3.62M	6.31M	4.9M	6.79M	6.43M
Gross Margin %	0.68%	0.6%	0.62%	0.46%	0.68%	0.67%	0.61%	0.56%	0.69%	0.75%
Gross Profit Growth %	-0.04%	-0.02%	0.11%	-0.36%	0.29%	-0.37%	0.74%	-0.22%	0.39%	-0.05%
Operating Expenses+	9.5M	12.82M	12.2M	10.89M	9.72M	11.07M	13.69M	13.73M	13.9M	13.19M
OpEx % of Revenue	1%	1.22%	1.08%	1.13%	1.16%	2.04%	1.33%	1.56%	1.41%	1.53%
Selling, General & Admin	9.4M	11.55M	11.93M	10.65M	9.53M	0	0	0	0	0
SG&A % of Revenue	0.99%	1.1%	1.06%	1.11%	1.14%	-	-	-	-	-
Research & Development	100.86K	1.27M	272.75K	245.64K	189.92K	307.85K	878.21K	1.15M	701.38K	858.77K
R&D % of Revenue	0.01%	0.12%	0.02%	0.03%	0.02%	0.06%	0.09%	0.13%	0.07%	0.1%
Other Operating Expenses	-5.35K	-5.09K	-4.93K	-7.23K	0	10.77M	12.81M	12.58M	13.2M	12.33M
Operating Income+	-3.06M	-6.51M	-5.23M	-8M	-4M	-7.45M	-7.38M	-8.83M	-7.11M	-6.76M
Operating Margin %	-0.32%	-0.62%	-0.46%	-0.83%	-0.48%	-1.37%	-0.72%	-1%	-0.72%	-0.78%
Operating Income Growth %	-2.87%	-1.13%	0.2%	-0.53%	0.5%	-0.86%	0.01%	-0.2%	0.19%	0.05%
EBITDA+	-2.96M	-6.35M	-4.66M	-7.12M	-3.74M	-7.36M	-7.3M	-8.76M	-7.04M	-6.72M
EBITDA Margin %	-0.31%	-0.61%	-0.41%	-0.74%	-0.45%	-1.35%	-0.71%	-1%	-0.72%	-0.78%
EBITDA Growth %	-3.26%	-1.15%	0.27%	-0.53%	0.47%	-0.97%	0.01%	-0.2%	0.2%	0.05%
D&A (Non-Cash Add-back)	97.38K	163.37K	573.15K	881.28K	256.47K	95.95K	73.83K	63.84K	62.32K	37.45K
EBIT	-3.06M	-6.51M	-5.23M	-6.46M	-7.64M	-7.45M	-7.38M	-8.83M	-7.11M	-6.76M
Net Interest Income+	3.84K	1.28K	9.3K	7.45K	1.54K	-18.08K	-16.36K	54.61K	125.53K	60.27K
Interest Income	3.84K	1.28K	9.3K	7.45K	1.54K	0	0	54.61K	125.53K	60.27K
Interest Expense	0	0	0	0	0	18.08K	16.36K	0	0	0
Other Income/Expense	-1.51K	-3.8K	4.37K	215	-3.56M	79.81K	502.41K	54.61K	125.53K	2.04M
Pretax Income+	-3.06M	-6.52M	-5.23M	-8M	-7.56M	-7.37M	-6.88M	-8.77M	-6.98M	-4.71M
Pretax Margin %	-0.32%	-0.62%	-0.46%	-0.83%	-0.9%	-1.36%	-0.67%	-1%	-0.71%	-0.55%
Income Tax+	36.16K	-19.1K	19.09K	23.99K	18.13K	15.5K	333	0	0	0
Effective Tax Rate %	1.79%	0.91%	0.99%	0.93%	1%	1%	0.99%	0.99%	0.99%	1%
Net Income+	-5.47M	-5.95M	-5.19M	-7.43M	-7.52M	-7.34M	-6.82M	-8.71M	-6.93M	-4.71M
Net Margin %	-0.58%	-0.57%	-0.46%	-0.77%	-0.9%	-1.35%	-0.66%	-0.99%	-0.71%	-0.55%
Net Income Growth %	-2.21%	-0.09%	0.13%	-0.43%	-0.01%	0.02%	0.07%	-0.28%	0.2%	0.32%
Net Income (Continuing)	-5.54M	-7.29M	-5.37M	-7.69M	-7.58M	-7.39M	-6.88M	-8.77M	-6.98M	-4.71M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	-1.14M	36.11K	256.74K	-11.4K	-67.27K	-94.43K	-152.54K	-219.28K	0	0
EPS (Diluted)+	-0.26	-0.22	-0.16	-0.21	-0.17	-0.12	-0.10	-0.12	-0.10	-0.06
EPS Growth %	-2.07%	0.15%	0.27%	-0.31%	0.19%	0.29%	0.17%	-0.2%	0.21%	0.38%
EPS (Basic)	-0.26	-0.22	-0.16	-0.21	-0.17	-0.12	-0.10	-0.12	-0.10	-0.06
Diluted Shares Outstanding	21.43M	26.97M	32.7M	35.3M	45.74M	63.06M	68.83M	70.61M	72.78M	79.79M
Basic Shares Outstanding	21.03M	26.97M	32.7M	35.3M	45.74M	63.06M	68.83M	70.61M	72.78M	79.79M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	11.82M	12.71M	12.02M	5.86M	6.08M	18.55M	18.93M	12.97M	10.79M	9.29M
Cash & Short-Term Investments	4.19M	3.6M	2.64M	743.43K	1.52M	14.22M	14.76M	8.72M	5.95M	3.26M
Cash Only	4.19M	3.6M	2.64M	743.43K	1.52M	14.22M	14.76M	8.72M	2.98M	3.26M
Short-Term Investments	0	0	0	0	0	0	0	0	2.98M	0
Accounts Receivable	1.85M	3.52M	3.26M	2.08M	1.71M	1.08M	943.27K	693.72K	312.66K	475.38K
Days Sales Outstanding	71.22	122.47	105.5	78.84	74.56	72.54	33.41	28.75	11.61	20.11
Inventory	4.26M	4.6M	3.38M	1.92M	1.62M	2.42M	1.54M	1.79M	2.64M	3.71M
Days Inventory Outstanding	509.87	402.34	286.01	135.08	222.69	486.45	140.92	167.53	317.3	617.36
Other Current Assets	304.6K	1.33M	2.31M	698.78K	710.66K	414.2K	1.31M	1.33M	1.37M	564.64K
Total Non-Current Assets+	985.18K	836.84K	3.61M	544.71K	479.12K	1.02M	875.99K	731.58K	577.04K	510.52K
Property, Plant & Equipment	235.94K	159.03K	141.76K	82.56K	60.95K	663.18K	574.22K	479.48K	374.26K	337.96K
Fixed Asset Turnover	40.23x	65.91x	79.58x	116.55x	137.39x	8.20x	17.95x	18.37x	26.26x	25.54x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	715.54K	660.46K	2.79M	435.27K	382.26K	329.25K	277.62K	227.96K	178.64K	148.4K
Long-Term Investments	16.35K	0	650K	0	0	0	0	0	0	0
Other Non-Current Assets	17.36K	17.36K	676.88K	26.88K	35.91K	24.15K	24.15K	24.15K	24.15K	24.15K
Total Assets+	12.81M	13.55M	15.63M	6.4M	6.56M	19.57M	19.81M	13.7M	11.37M	9.8M
Asset Turnover	0.74x	0.77x	0.72x	1.50x	1.28x	0.28x	0.52x	0.64x	0.86x	0.88x
Asset Growth %	-0.27%	0.06%	0.15%	-0.59%	0.02%	1.99%	0.01%	-0.31%	-0.17%	-0.14%
Total Current Liabilities+	3.64M	5.01M	6.73M	4.87M	4.93M	2.88M	3.1M	3.3M	3.08M	3.74M
Accounts Payable	2.09M	2.58M	977.62K	2.87M	2.74M	868.11K	1.18M	1.91M	1.1M	1.02M
Days Payables Outstanding	250.05	225.2	82.74	201.76	376.27	174.49	107.53	178.17	132.31	169.82
Short-Term Debt	0	0	0	0	0	276.18K	0	0	0	0
Deferred Revenue (Current)	0	1000K	1000K	521.8K	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	340.48K	242.59K	0	0	0	0
Current Ratio	3.24x	2.54x	1.79x	1.20x	1.23x	6.45x	6.11x	3.93x	3.51x	2.48x
Quick Ratio	2.08x	1.62x	1.28x	0.81x	0.90x	5.61x	5.62x	3.39x	2.65x	1.49x
Cash Conversion Cycle	331.03	299.61	308.77	12.17	-79.03	384.51	66.8	18.11	196.6	467.65
Total Non-Current Liabilities+	0	36.11K	1.4M	0	0	586.59K	497.04K	395.98K	282.29K	220.25K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	586.59K	497.04K	395.98K	282.29K	220.25K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	1	0	0	1	0
Total Liabilities	3.64M	5.01M	8.13M	4.87M	4.93M	3.46M	3.59M	3.7M	3.36M	3.96M
Total Debt+	0	0	0	0	15.98K	942.6K	586.59K	497.04K	395.98K	349.05K
Net Debt	-4.19M	-3.6M	-2.64M	-743.43K	-1.5M	-13.28M	-14.18M	-8.22M	-2.58M	-2.91M
Debt / Equity	-	-	-	-	0.01x	0.06x	0.04x	0.05x	0.05x	0.06x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-412.21x	-451.01x	-	-	-
Total Equity+	9.17M	8.54M	7.5M	1.53M	1.63M	16.11M	16.22M	10.01M	8.01M	5.83M
Equity Growth %	-0.39%	-0.07%	-0.12%	-0.8%	0.07%	8.89%	0.01%	-0.38%	-0.2%	-0.27%
Book Value per Share	0.43	0.32	0.23	0.04	0.04	0.26	0.24	0.14	0.11	0.07
Total Shareholders' Equity	10.31M	8.5M	7.24M	1.54M	1.7M	16.2M	16.37M	10.23M	8.01M	5.83M
Common Stock	22.68K	31.72K	34.59K	36.33K	49.41K	64.17K	68.15K	69.31K	75.88K	78.05K
Retained Earnings	-67.43M	-73.38M	-78.57M	-86M	-93.52M	-100.89M	-107.7M	-116.41M	-123.34M	-128.05M
Treasury Stock	-911.52K	-911.52K	-911.52K	-911.52K	-911.52K	-911.52K	-911.52K	-911.52K	-911.52K	-911.52K
Accumulated OCI	-566.48K	-659.14K	-721.62K	-788.68K	0	0	0	0	0	0
Minority Interest	-1.14M	36.11K	256.74K	-11.4K	-67.27K	-94.43K	-152.54K	-219.28K	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.95M	-5.4M	-1.23M	-1.63M	-1.78M	-6.98M	-4.02M	-6.03M	-5.33M	-2.92M
Operating CF Margin %	-0.31%	-0.52%	-0.11%	-0.17%	-0.21%	-1.28%	-0.39%	-0.68%	-0.54%	-0.34%
Operating CF Growth %	-8.82%	-0.83%	0.77%	-0.32%	-0.09%	-2.93%	0.42%	-0.5%	0.12%	0.45%
Net Income	-5.54M	-7.29M	-5.37M	-7.69M	-7.58M	-7.39M	-6.88M	-8.77M	-6.93M	-4.71M
Depreciation & Amortization	97.38K	163.37K	573.15K	881.28K	256.47K	95.95K	73.83K	144.38K	150.36K	134.84K
Stock-Based Compensation	1.13M	1.85M	651.41K	409.02K	183.89K	1.35M	1.58M	1.82M	1.88M	1.71M
Deferred Taxes	1.25M	-1.05M	182.76K	260.13K	0	-97.89K	-518.77K	0	0	0
Other Non-Cash Items	1.13M	1.85M	157.58K	2.74M	3.55M	1.67M	652.76K	1.33M	968.16K	579.8K
Working Capital Changes	-1.01M	-914.04K	2.58M	1.77M	1.81M	-1.81M	1.07M	-549.72K	-1.4M	-631K
Change in Receivables	-207.25K	-1.09M	256.02K	-635.48K	367.79K	630.01K	137.38K	249.56K	309.94K	-162.71K
Change in Inventory	-875.03K	-509.46K	1M	914.61K	300.54K	-799.67K	878.67K	-833.12K	-1.1M	-1.08M
Change in Payables	173.07K	486.35K	-612.96K	905.94K	16.89K	-1.87M	308.18K	729.94K	-806.11K	414.59K
Cash from Investing+	-3.73M	8.21K	-199.18K	-15.42K	-9.92K	-21.44K	-15.19K	-8.53K	-2.97M	2.97M
Capital Expenditures	-77.52K	-30.96K	-199.18K	-7.4K	-9.92K	-21.44K	-15.19K	-8.53K	-4.88K	-10.12K
CapEx % of Revenue	0.01%	0%	0.02%	0%	0%	0%	0%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-9.94K	39.16K	-193.17K	0	0	0	0	0	-2.97M	0
Cash from Financing+	500K	4.8M	463.34K	-250K	2.56M	19.71M	4.57M	-8.54K	2.56M	233.77K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	500K	0	62.5K	-250K	337.5K	19.45M	4.6M	0	0	51.75K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.02M	-5.43M	-1.43M	-1.64M	-1.79M	-7.01M	-4.03M	-6.04M	-5.33M	-2.93M
FCF Margin %	-0.32%	-0.52%	-0.13%	-0.17%	-0.21%	-1.29%	-0.39%	-0.69%	-0.54%	-0.34%
FCF Growth %	-11.88%	-0.8%	0.74%	-0.14%	-0.09%	-2.92%	0.42%	-0.5%	0.12%	0.45%
FCF per Share	-0.14	-0.20	-0.04	-0.05	-0.04	-0.11	-0.06	-0.09	-0.07	-0.04
FCF Conversion (FCF/Net Income)	0.54x	0.91x	0.24x	0.22x	0.24x	0.95x	0.59x	0.69x	0.77x	0.62x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-45.17%	-67.19%	-64.69%	-164.62%	-476.7%	-82.74%	-42.19%	-66.4%	-76.91%	-68.09%
Return on Invested Capital (ROIC)	-47.29%	-98.64%	-80.14%	-212.43%	-656.91%	-378.46%	-227.58%	-346.1%	-147.66%	-121.32%
Gross Margin	67.88%	60.16%	61.77%	46.05%	68.28%	66.6%	61.25%	55.65%	69.12%	74.56%
Net Margin	-57.6%	-56.73%	-45.97%	-77.24%	-89.85%	-134.94%	-66.17%	-98.87%	-70.51%	-54.62%
Debt / Equity	-	-	-	-	0.01x	0.06x	0.04x	0.05x	0.05x	0.06x
Interest Coverage	-	-	-	-	-	-412.21x	-451.01x	-	-	-
FCF Conversion	0.54x	0.91x	0.24x	0.22x	0.24x	0.95x	0.59x	0.69x	0.77x	0.62x
Revenue Growth	-8.14%	10.43%	7.63%	-14.71%	-12.97%	-35.07%	89.52%	-14.54%	11.6%	-12.19%

Revenue by Segment

	2012	2013	2014	2015	2016
Handpieces	-	-	-	6.41M	-
Handpieces Growth	-	-	-	-	-
Instruments	2.15M	2.67M	2.57M	-	-
Instruments Growth	-	24.47%	-3.85%	-	-
Other Product	-	-	136.85K	-	-
Other Product Growth	-	-	-	-	-
Equipment	6.34M	7.29M	-	-	-
Equipment Growth	-	14.99%	-	-	-
Other Credit Derivatives	157.47K	44.58K	-	-	-
Other Credit Derivatives Growth	-	-71.69%	-	-	-

Revenue by Geography

	2012	2013	2014	2015	2016
International	-	-	-	-	14.77M
International Growth	-	-	-	-	-
Domestic	-	-	-	-	6.2M
Domestic Growth	-	-	-	-	-
Other Foreign	3.75M	4.41M	5.58M	5.99M	-
Other Foreign Growth	-	17.50%	26.56%	7.32%	-
U S	-	5.3M	4.66M	3.3M	-
U S Growth	-	-	-12.15%	-29.22%	-
C A	-	305.17K	100.32K	211.03K	-
C A Growth	-	-	-67.13%	110.36%	-
UNITED STATES	4.34M	-	-	-	-
UNITED STATES Growth	-	-	-	-	-
CANADA	553.98K	-	-	-	-
CANADA Growth	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Milestone Scientific Inc. (MLSS) reported $9.1M in revenue for fiscal year 2024. This represents a 8% increase from $8.4M in 2011.

Milestone Scientific Inc. (MLSS) saw revenue decline by 12.2% over the past year.

Milestone Scientific Inc. (MLSS) reported a net loss of $7.0M for fiscal year 2024.

Dividend & Returns

Milestone Scientific Inc. (MLSS) has a return on equity (ROE) of -68.1%. Negative ROE indicates the company is unprofitable.

Milestone Scientific Inc. (MLSS) had negative free cash flow of $5.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Milestone Scientific Inc. (MLSS) 10-Year Financial Performance & Capital Metrics

MLSS • • Industrial / General

HealthcareMedical InstrumentsSurgical & Interventional DevicesSpecialized Therapeutic Devices

Revenue $9M -12.2%
EBITDA -$7M +4.6%
Net Income -$5M +32.0%
EPS (Diluted) -0.06 +37.9%
Gross Margin 74.56% +7.9%
EBITDA Margin -77.86% -8.6%
Operating Margin -78.3% -8.3%
Net Margin -54.62% +22.5%
ROE -68.09% +11.5%
ROIC -121.32% +17.8%
Debt/Equity 0.06 +21.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 5 (bottom 5%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-1.79%

5Y0.6%

3Y-5.74%

TTM7.84%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-50.9%

EPS CAGR

10Y-

5Y-

3Y-

TTM-41.94%

ROCE

10Y Avg-92.65%

5Y Avg-72.17%

3Y Avg-78.44%

Latest-94.19%

Peer Comparison

Specialized Therapeutic Devices

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RMDResMed Inc.	38.05B	260.70	27.41	9.84%	27.35%	23.49%	4.37%	0.14
ZJYLJin Medical International Ltd.	22.54M	0.14	6.13	18.57%	10.94%	16.93%		0.41
FEMYFemasys Inc.	38.2M	0.64	-0.76	51.97%	-9.61%	-434.6%		3.23
NYXHNyxoah S.A.	221.59M	5.15	-2.85	3.98%	-14.85%	-164.31%		0.20
MLSSMilestone Scientific Inc.	22.8M	0.29	-4.91	-12.19%	-76.78%	-208.8%		0.06
NVCRNovoCure Limited	1.55B	13.80	-8.85	18.82%	-27.66%	-52.05%		1.90
EKSOEkso Bionics Holdings, Inc.	22.43M	8.55	-15.27	-1.94%	-70.74%	-107.8%		0.47
PLSEPulse Biosciences, Inc.	955.52M	14.10	-15.33		-868.99%	-80.62%		0.08

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	9.49M	10.48M	11.28M	9.62M	8.37M	5.44M	10.3M	8.81M	9.83M	8.63M
Revenue Growth %	-0.08%	0.1%	0.08%	-0.15%	-0.13%	-0.35%	0.9%	-0.15%	0.12%	-0.12%
Cost of Goods Sold+	3.05M	4.18M	4.31M	5.19M	2.66M	1.82M	3.99M	3.91M	3.03M	2.2M
COGS % of Revenue	0.32%	0.4%	0.38%	0.54%	0.32%	0.33%	0.39%	0.44%	0.31%	0.25%
Gross Profit+	6.44M	6.31M	6.97M	4.43M	5.72M	3.62M	6.31M	4.9M	6.79M	6.43M
Gross Margin %	0.68%	0.6%	0.62%	0.46%	0.68%	0.67%	0.61%	0.56%	0.69%	0.75%
Gross Profit Growth %	-0.04%	-0.02%	0.11%	-0.36%	0.29%	-0.37%	0.74%	-0.22%	0.39%	-0.05%
Operating Expenses+	9.5M	12.82M	12.2M	10.89M	9.72M	11.07M	13.69M	13.73M	13.9M	13.19M
OpEx % of Revenue	1%	1.22%	1.08%	1.13%	1.16%	2.04%	1.33%	1.56%	1.41%	1.53%
Selling, General & Admin	9.4M	11.55M	11.93M	10.65M	9.53M	0	0	0	0	0
SG&A % of Revenue	0.99%	1.1%	1.06%	1.11%	1.14%	-	-	-	-	-
Research & Development	100.86K	1.27M	272.75K	245.64K	189.92K	307.85K	878.21K	1.15M	701.38K	858.77K
R&D % of Revenue	0.01%	0.12%	0.02%	0.03%	0.02%	0.06%	0.09%	0.13%	0.07%	0.1%
Other Operating Expenses	-5.35K	-5.09K	-4.93K	-7.23K	0	10.77M	12.81M	12.58M	13.2M	12.33M
Operating Income+	-3.06M	-6.51M	-5.23M	-8M	-4M	-7.45M	-7.38M	-8.83M	-7.11M	-6.76M
Operating Margin %	-0.32%	-0.62%	-0.46%	-0.83%	-0.48%	-1.37%	-0.72%	-1%	-0.72%	-0.78%
Operating Income Growth %	-2.87%	-1.13%	0.2%	-0.53%	0.5%	-0.86%	0.01%	-0.2%	0.19%	0.05%
EBITDA+	-2.96M	-6.35M	-4.66M	-7.12M	-3.74M	-7.36M	-7.3M	-8.76M	-7.04M	-6.72M
EBITDA Margin %	-0.31%	-0.61%	-0.41%	-0.74%	-0.45%	-1.35%	-0.71%	-1%	-0.72%	-0.78%
EBITDA Growth %	-3.26%	-1.15%	0.27%	-0.53%	0.47%	-0.97%	0.01%	-0.2%	0.2%	0.05%
D&A (Non-Cash Add-back)	97.38K	163.37K	573.15K	881.28K	256.47K	95.95K	73.83K	63.84K	62.32K	37.45K
EBIT	-3.06M	-6.51M	-5.23M	-6.46M	-7.64M	-7.45M	-7.38M	-8.83M	-7.11M	-6.76M
Net Interest Income+	3.84K	1.28K	9.3K	7.45K	1.54K	-18.08K	-16.36K	54.61K	125.53K	60.27K
Interest Income	3.84K	1.28K	9.3K	7.45K	1.54K	0	0	54.61K	125.53K	60.27K
Interest Expense	0	0	0	0	0	18.08K	16.36K	0	0	0
Other Income/Expense	-1.51K	-3.8K	4.37K	215	-3.56M	79.81K	502.41K	54.61K	125.53K	2.04M
Pretax Income+	-3.06M	-6.52M	-5.23M	-8M	-7.56M	-7.37M	-6.88M	-8.77M	-6.98M	-4.71M
Pretax Margin %	-0.32%	-0.62%	-0.46%	-0.83%	-0.9%	-1.36%	-0.67%	-1%	-0.71%	-0.55%
Income Tax+	36.16K	-19.1K	19.09K	23.99K	18.13K	15.5K	333	0	0	0
Effective Tax Rate %	1.79%	0.91%	0.99%	0.93%	1%	1%	0.99%	0.99%	0.99%	1%
Net Income+	-5.47M	-5.95M	-5.19M	-7.43M	-7.52M	-7.34M	-6.82M	-8.71M	-6.93M	-4.71M
Net Margin %	-0.58%	-0.57%	-0.46%	-0.77%	-0.9%	-1.35%	-0.66%	-0.99%	-0.71%	-0.55%
Net Income Growth %	-2.21%	-0.09%	0.13%	-0.43%	-0.01%	0.02%	0.07%	-0.28%	0.2%	0.32%
Net Income (Continuing)	-5.54M	-7.29M	-5.37M	-7.69M	-7.58M	-7.39M	-6.88M	-8.77M	-6.98M	-4.71M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	-1.14M	36.11K	256.74K	-11.4K	-67.27K	-94.43K	-152.54K	-219.28K	0	0
EPS (Diluted)+	-0.26	-0.22	-0.16	-0.21	-0.17	-0.12	-0.10	-0.12	-0.10	-0.06
EPS Growth %	-2.07%	0.15%	0.27%	-0.31%	0.19%	0.29%	0.17%	-0.2%	0.21%	0.38%
EPS (Basic)	-0.26	-0.22	-0.16	-0.21	-0.17	-0.12	-0.10	-0.12	-0.10	-0.06
Diluted Shares Outstanding	21.43M	26.97M	32.7M	35.3M	45.74M	63.06M	68.83M	70.61M	72.78M	79.79M
Basic Shares Outstanding	21.03M	26.97M	32.7M	35.3M	45.74M	63.06M	68.83M	70.61M	72.78M	79.79M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	11.82M	12.71M	12.02M	5.86M	6.08M	18.55M	18.93M	12.97M	10.79M	9.29M
Cash & Short-Term Investments	4.19M	3.6M	2.64M	743.43K	1.52M	14.22M	14.76M	8.72M	5.95M	3.26M
Cash Only	4.19M	3.6M	2.64M	743.43K	1.52M	14.22M	14.76M	8.72M	2.98M	3.26M
Short-Term Investments	0	0	0	0	0	0	0	0	2.98M	0
Accounts Receivable	1.85M	3.52M	3.26M	2.08M	1.71M	1.08M	943.27K	693.72K	312.66K	475.38K
Days Sales Outstanding	71.22	122.47	105.5	78.84	74.56	72.54	33.41	28.75	11.61	20.11
Inventory	4.26M	4.6M	3.38M	1.92M	1.62M	2.42M	1.54M	1.79M	2.64M	3.71M
Days Inventory Outstanding	509.87	402.34	286.01	135.08	222.69	486.45	140.92	167.53	317.3	617.36
Other Current Assets	304.6K	1.33M	2.31M	698.78K	710.66K	414.2K	1.31M	1.33M	1.37M	564.64K
Total Non-Current Assets+	985.18K	836.84K	3.61M	544.71K	479.12K	1.02M	875.99K	731.58K	577.04K	510.52K
Property, Plant & Equipment	235.94K	159.03K	141.76K	82.56K	60.95K	663.18K	574.22K	479.48K	374.26K	337.96K
Fixed Asset Turnover	40.23x	65.91x	79.58x	116.55x	137.39x	8.20x	17.95x	18.37x	26.26x	25.54x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	715.54K	660.46K	2.79M	435.27K	382.26K	329.25K	277.62K	227.96K	178.64K	148.4K
Long-Term Investments	16.35K	0	650K	0	0	0	0	0	0	0
Other Non-Current Assets	17.36K	17.36K	676.88K	26.88K	35.91K	24.15K	24.15K	24.15K	24.15K	24.15K
Total Assets+	12.81M	13.55M	15.63M	6.4M	6.56M	19.57M	19.81M	13.7M	11.37M	9.8M
Asset Turnover	0.74x	0.77x	0.72x	1.50x	1.28x	0.28x	0.52x	0.64x	0.86x	0.88x
Asset Growth %	-0.27%	0.06%	0.15%	-0.59%	0.02%	1.99%	0.01%	-0.31%	-0.17%	-0.14%
Total Current Liabilities+	3.64M	5.01M	6.73M	4.87M	4.93M	2.88M	3.1M	3.3M	3.08M	3.74M
Accounts Payable	2.09M	2.58M	977.62K	2.87M	2.74M	868.11K	1.18M	1.91M	1.1M	1.02M
Days Payables Outstanding	250.05	225.2	82.74	201.76	376.27	174.49	107.53	178.17	132.31	169.82
Short-Term Debt	0	0	0	0	0	276.18K	0	0	0	0
Deferred Revenue (Current)	0	1000K	1000K	521.8K	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	340.48K	242.59K	0	0	0	0
Current Ratio	3.24x	2.54x	1.79x	1.20x	1.23x	6.45x	6.11x	3.93x	3.51x	2.48x
Quick Ratio	2.08x	1.62x	1.28x	0.81x	0.90x	5.61x	5.62x	3.39x	2.65x	1.49x
Cash Conversion Cycle	331.03	299.61	308.77	12.17	-79.03	384.51	66.8	18.11	196.6	467.65
Total Non-Current Liabilities+	0	36.11K	1.4M	0	0	586.59K	497.04K	395.98K	282.29K	220.25K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	586.59K	497.04K	395.98K	282.29K	220.25K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	1	0	0	1	0
Total Liabilities	3.64M	5.01M	8.13M	4.87M	4.93M	3.46M	3.59M	3.7M	3.36M	3.96M
Total Debt+	0	0	0	0	15.98K	942.6K	586.59K	497.04K	395.98K	349.05K
Net Debt	-4.19M	-3.6M	-2.64M	-743.43K	-1.5M	-13.28M	-14.18M	-8.22M	-2.58M	-2.91M
Debt / Equity	-	-	-	-	0.01x	0.06x	0.04x	0.05x	0.05x	0.06x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-412.21x	-451.01x	-	-	-
Total Equity+	9.17M	8.54M	7.5M	1.53M	1.63M	16.11M	16.22M	10.01M	8.01M	5.83M
Equity Growth %	-0.39%	-0.07%	-0.12%	-0.8%	0.07%	8.89%	0.01%	-0.38%	-0.2%	-0.27%
Book Value per Share	0.43	0.32	0.23	0.04	0.04	0.26	0.24	0.14	0.11	0.07
Total Shareholders' Equity	10.31M	8.5M	7.24M	1.54M	1.7M	16.2M	16.37M	10.23M	8.01M	5.83M
Common Stock	22.68K	31.72K	34.59K	36.33K	49.41K	64.17K	68.15K	69.31K	75.88K	78.05K
Retained Earnings	-67.43M	-73.38M	-78.57M	-86M	-93.52M	-100.89M	-107.7M	-116.41M	-123.34M	-128.05M
Treasury Stock	-911.52K	-911.52K	-911.52K	-911.52K	-911.52K	-911.52K	-911.52K	-911.52K	-911.52K	-911.52K
Accumulated OCI	-566.48K	-659.14K	-721.62K	-788.68K	0	0	0	0	0	0
Minority Interest	-1.14M	36.11K	256.74K	-11.4K	-67.27K	-94.43K	-152.54K	-219.28K	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.95M	-5.4M	-1.23M	-1.63M	-1.78M	-6.98M	-4.02M	-6.03M	-5.33M	-2.92M
Operating CF Margin %	-0.31%	-0.52%	-0.11%	-0.17%	-0.21%	-1.28%	-0.39%	-0.68%	-0.54%	-0.34%
Operating CF Growth %	-8.82%	-0.83%	0.77%	-0.32%	-0.09%	-2.93%	0.42%	-0.5%	0.12%	0.45%
Net Income	-5.54M	-7.29M	-5.37M	-7.69M	-7.58M	-7.39M	-6.88M	-8.77M	-6.93M	-4.71M
Depreciation & Amortization	97.38K	163.37K	573.15K	881.28K	256.47K	95.95K	73.83K	144.38K	150.36K	134.84K
Stock-Based Compensation	1.13M	1.85M	651.41K	409.02K	183.89K	1.35M	1.58M	1.82M	1.88M	1.71M
Deferred Taxes	1.25M	-1.05M	182.76K	260.13K	0	-97.89K	-518.77K	0	0	0
Other Non-Cash Items	1.13M	1.85M	157.58K	2.74M	3.55M	1.67M	652.76K	1.33M	968.16K	579.8K
Working Capital Changes	-1.01M	-914.04K	2.58M	1.77M	1.81M	-1.81M	1.07M	-549.72K	-1.4M	-631K
Change in Receivables	-207.25K	-1.09M	256.02K	-635.48K	367.79K	630.01K	137.38K	249.56K	309.94K	-162.71K
Change in Inventory	-875.03K	-509.46K	1M	914.61K	300.54K	-799.67K	878.67K	-833.12K	-1.1M	-1.08M
Change in Payables	173.07K	486.35K	-612.96K	905.94K	16.89K	-1.87M	308.18K	729.94K	-806.11K	414.59K
Cash from Investing+	-3.73M	8.21K	-199.18K	-15.42K	-9.92K	-21.44K	-15.19K	-8.53K	-2.97M	2.97M
Capital Expenditures	-77.52K	-30.96K	-199.18K	-7.4K	-9.92K	-21.44K	-15.19K	-8.53K	-4.88K	-10.12K
CapEx % of Revenue	0.01%	0%	0.02%	0%	0%	0%	0%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-9.94K	39.16K	-193.17K	0	0	0	0	0	-2.97M	0
Cash from Financing+	500K	4.8M	463.34K	-250K	2.56M	19.71M	4.57M	-8.54K	2.56M	233.77K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	500K	0	62.5K	-250K	337.5K	19.45M	4.6M	0	0	51.75K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.02M	-5.43M	-1.43M	-1.64M	-1.79M	-7.01M	-4.03M	-6.04M	-5.33M	-2.93M
FCF Margin %	-0.32%	-0.52%	-0.13%	-0.17%	-0.21%	-1.29%	-0.39%	-0.69%	-0.54%	-0.34%
FCF Growth %	-11.88%	-0.8%	0.74%	-0.14%	-0.09%	-2.92%	0.42%	-0.5%	0.12%	0.45%
FCF per Share	-0.14	-0.20	-0.04	-0.05	-0.04	-0.11	-0.06	-0.09	-0.07	-0.04
FCF Conversion (FCF/Net Income)	0.54x	0.91x	0.24x	0.22x	0.24x	0.95x	0.59x	0.69x	0.77x	0.62x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-45.17%	-67.19%	-64.69%	-164.62%	-476.7%	-82.74%	-42.19%	-66.4%	-76.91%	-68.09%
Return on Invested Capital (ROIC)	-47.29%	-98.64%	-80.14%	-212.43%	-656.91%	-378.46%	-227.58%	-346.1%	-147.66%	-121.32%
Gross Margin	67.88%	60.16%	61.77%	46.05%	68.28%	66.6%	61.25%	55.65%	69.12%	74.56%
Net Margin	-57.6%	-56.73%	-45.97%	-77.24%	-89.85%	-134.94%	-66.17%	-98.87%	-70.51%	-54.62%
Debt / Equity	-	-	-	-	0.01x	0.06x	0.04x	0.05x	0.05x	0.06x
Interest Coverage	-	-	-	-	-	-412.21x	-451.01x	-	-	-
FCF Conversion	0.54x	0.91x	0.24x	0.22x	0.24x	0.95x	0.59x	0.69x	0.77x	0.62x
Revenue Growth	-8.14%	10.43%	7.63%	-14.71%	-12.97%	-35.07%	89.52%	-14.54%	11.6%	-12.19%

Revenue by Segment

	2012	2013	2014	2015	2016
Handpieces	-	-	-	6.41M	-
Handpieces Growth	-	-	-	-	-
Instruments	2.15M	2.67M	2.57M	-	-
Instruments Growth	-	24.47%	-3.85%	-	-
Other Product	-	-	136.85K	-	-
Other Product Growth	-	-	-	-	-
Equipment	6.34M	7.29M	-	-	-
Equipment Growth	-	14.99%	-	-	-
Other Credit Derivatives	157.47K	44.58K	-	-	-
Other Credit Derivatives Growth	-	-71.69%	-	-	-

Revenue by Geography

	2012	2013	2014	2015	2016
International	-	-	-	-	14.77M
International Growth	-	-	-	-	-
Domestic	-	-	-	-	6.2M
Domestic Growth	-	-	-	-	-
Other Foreign	3.75M	4.41M	5.58M	5.99M	-
Other Foreign Growth	-	17.50%	26.56%	7.32%	-
U S	-	5.3M	4.66M	3.3M	-
U S Growth	-	-	-12.15%	-29.22%	-
C A	-	305.17K	100.32K	211.03K	-
C A Growth	-	-	-67.13%	110.36%	-
UNITED STATES	4.34M	-	-	-	-
UNITED STATES Growth	-	-	-	-	-
CANADA	553.98K	-	-	-	-
CANADA Growth	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Milestone Scientific Inc. (MLSS) reported $9.1M in revenue for fiscal year 2024. This represents a 8% increase from $8.4M in 2011.

Milestone Scientific Inc. (MLSS) saw revenue decline by 12.2% over the past year.

Milestone Scientific Inc. (MLSS) reported a net loss of $7.0M for fiscal year 2024.

Dividend & Returns

Milestone Scientific Inc. (MLSS) has a return on equity (ROE) of -68.1%. Negative ROE indicates the company is unprofitable.

Milestone Scientific Inc. (MLSS) had negative free cash flow of $5.3M in fiscal year 2024, likely due to heavy capital investments.